Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 6, 1997, Pages 261-264

  Muck W ^a   Ritter, W ^a   Dietrich, H ^a   Frey, R ^a   Kuhlmann, J ^a  

^a BAYER AG   (Germany)

Author keywords

Absorption; Antacid; Cerivastatin; Cimetidine; Cytochrome P450 inhibition; H2 antagonist; HMG CoA reductase inhibitor; Maalox 70; Pharmacokinetic interaction

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; CERIVASTATIN; CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ALUMINUM HYDROXIDE; ANALYSIS OF VARIANCE; ANTACIDS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIMETIDINE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMBINATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; MAGNESIUM HYDROXIDE; MALE; PYRIDINES; RADIOIMMUNOASSAY;

EID: 0344104412     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Angerbauer R, Bischoff H, Steinke W, Ritter W 1994 BAY w 6228. Drugs Future 19: 537-541
2. Boberg M, Angerbauer R, Fey P, Kanhai W, Karl W, Kern A, Ploschke J, Radtke M 1997 Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25: 321-331
3. Krol GJ, Beck GW, Ritter W, Lettieri JT 1993 LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 11: 1269-1275
4. Krol GJ, Beck GW, Ritter W, Lettieri JT, Ness GC, Lopez D, Heller A 1994 Determination of rivastatin levels in plasma samples by HPLC and enzyme inhibition assay. In: Reid E, Hill HM, Wilson ID (eds) Biofluid and Tissue Analysis for Drugs, Including Hypolipidaemics. Methodological Surveys in Bioanalysis of Drugs (Vol. 23). Royal Chem Soc, Cambridge, pp 147-156
5. Mazzu A, Lettieri J, Kaiser L, Frey R, Heller AH 1993 Ascending multiple dose safety, tolerability and pharmacokinetics of rivastatin in humans. Clin Pharmacol Ther 53: 230
6. Mazzu A, Lettieri J, Heller AH 1997 Pharmacokinetics of cerivastatin administration with and without food in the morning and evening. Abstract accepted for the 68th Meeting of the European Atherosclerosis Society (EAS), May 7-10, Brügge, Belgium
7. Mück W, Ritter W, Ochmann K, Kuhlmann J 1997 Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Naunyn Schmiedeberg's Arch Pharmacol 355 (Suppl): R127
8. Nazario M 1986 The hepatic and renal mechanisms of drug interactions with cimetidine. Drug Intell Clin Pharm 20: 342-348
9. Ritter W, Frey R, Krol G, Kuhlmann J 1993 Rivastatin single dose pharmacokinetics. Clin Pharmacol Ther 53: 210
10. Somogyi A, Muirhead M 1987 Pharmacokinetic interactions of cimetidine. Clin Pharmacokinet 12: 321-366
11. Vyas KP, Kari PH, Wang RW, Lu AY 1990 Biotransformation of lovastatin. III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes. Biochem Pharmacol 39: 67-73
12. Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP, Vyas KP 1991 Biotransformation of lovastatin. IV: Identification of cytochrome P4503A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290: 355-361
13. Yang BB, Smithers JA, Abel RB, Stern RH, Sedman AJ, Olson JC 1996 Effects of Maalox TC on pharmacokinetics and pharmacodynamics of atorvastatin. Pharm Res 13 (Suppl): 437